1
|
Egert A, Karschnia P, Huttner A, Baehring JM, Kaulen LD. P11.54.A Factors effecting early diagnosis in neurolymphomatosis. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
Abstract
Background
Neurolymphomatosis is defined as infiltration of the peripheral nervous system by non-Hodgkin lymphoma (NHL). Given its rarity, correct diagnosis is often delayed. Here we assessed diagnostic work-up and factors affecting timely diagnosis at a tertiary referral center.
Material and Methods
The quality control database of the Section of Neuro-Oncology at Yale Cancer Center was searched for neurolymphomatosis cases seen between 2000 and 2021. Clinical, radiological and pathological findings were collected. Factors affecting the interval from symptom onset to diagnosis were investigated in univariate analysis using SPSS version 27. P-values <0.05 were considered statistically significant.
Results
We identified 22 cases of neurolymphomatosis (primary n=7, secondary n=15) with secondary disease diagnosed a median of 16 months (range: 4-144) after NHL. Patients presented with painful polyneuropathy (n=16), painless polyneuropathy (n=4), cranial neuropathy (n=3), and autonomic neuropathy (n=1). Diagnosis was nerve biopsy-based (n=11) or resulted from integration of imaging findings (n=11) with NHL history (n=5) or detection of NHL in the cerebrospinal fluid (n=6), respectively. Lesions localized to nerve roots (n=16), peripheral nerves (n=12), plexus (n=10), cranial (n=3) or autonomic (n=1) nerves. Histologically, most cases were classified as diffuse-large B-cell lymphoma (n=18). Median interval from symptom onset to diagnosis was 3 months (range: 1-12). Secondary neurolymphomatosis (p=0.02) and FDG-PET imaging (p<0.01) were associated with an earlier diagnosis.
Conclusion
Diagnosis of neurolymphomatosis requires a high degree of clinical suspicion with subsequent integration of clinical, radiological and pathological findings. FDG-PET, the imaging gold standard, and a known NHL history correlated with an earlier diagnosis.
Collapse
Affiliation(s)
- A Egert
- Department of Neurology, Yale School of Medicine , New Haven, CT , United States
| | - P Karschnia
- Department of Neurology, Yale School of Medicine , New Haven, CT , United States
- Department of Neurosurgery, Ludwig-Maximilians-Universität (LMU) , Munich , Germany
| | - A Huttner
- Department of Pathology, Yale School of Medicine , New Haven, CT , United States
| | - J M Baehring
- Department of Neurology, Yale School of Medicine , New Haven, CT , United States
- Department of Neurosurgery, Yale School of Medicine , New Haven, CT , United States
| | - L D Kaulen
- Department of Neurology, Yale School of Medicine , New Haven, CT , United States
- Department of Neurology, Heidelberg University Hospital , Heidelberg , Germany
- Clinical Cooperation Unit Neuro-Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg , Germany
| |
Collapse
|
2
|
Raftopulos NL, Washaya TC, Niederprüm A, Egert A, Hakeem-Sanni MF, Varney B, Aishah A, Georgieva ML, Olsson E, Dos Santos DZ, Nassar ZD, Cochran BJ, Nagarajan SR, Kakani MS, Hastings JF, Croucher DR, Rye KA, Butler LM, Grewal T, Hoy AJ. Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer Metab 2022; 10:1. [PMID: 35033184 PMCID: PMC8760736 DOI: 10.1186/s40170-021-00278-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 11/24/2021] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Prostate cancer growth is driven by androgen receptor signaling, and advanced disease is initially treatable by depleting circulating androgens. However, prostate cancer cells inevitably adapt, resulting in disease relapse with incurable castrate-resistant prostate cancer. Androgen deprivation therapy has many side effects, including hypercholesterolemia, and more aggressive and castrate-resistant prostate cancers typically feature cellular accumulation of cholesterol stored in the form of cholesteryl esters. As cholesterol is a key substrate for de novo steroidogenesis in prostate cells, this study hypothesized that castrate-resistant/advanced prostate cancer cell growth is influenced by the availability of extracellular, low-density lipoprotein (LDL)-derived, cholesterol, which is coupled to intracellular cholesteryl ester homeostasis. METHODS C4-2B and PC3 prostate cancer cells were cultured in media supplemented with fetal calf serum (FCS), charcoal-stripped FCS (CS-FCS), lipoprotein-deficient FCS (LPDS), or charcoal-stripped LPDS (CS-LPDS) and analyzed by a variety of biochemical techniques. Cell viability and proliferation were measured by MTT assay and Incucyte, respectively. RESULTS Reducing lipoprotein availability led to a reduction in cholesteryl ester levels and cell growth in C4-2B and PC3 cells, with concomitant reductions in PI3K/mTOR and p38MAPK signaling. This reduced growth in LPDS-containing media was fully recovered by supplementation of exogenous low-density lipoprotein (LDL), but LDL only partially rescued growth of cells cultured with CS-LPDS. This growth pattern was not associated with changes in androgen receptor signaling but rather increased p38MAPK and MEK1/ERK/MSK1 activation. The ability of LDL supplementation to rescue cell growth required cholesterol esterification as well as cholesteryl ester hydrolysis activity. Further, growth of cells cultured in low androgen levels (CS-FCS) was suppressed when cholesteryl ester hydrolysis was inhibited. CONCLUSIONS Overall, these studies demonstrate that androgen-independent prostate cancer cell growth can be influenced by extracellular lipid levels and LDL-cholesterol availability and that uptake of extracellular cholesterol, through endocytosis of LDL-derived cholesterol and subsequent delivery and storage in the lipid droplet as cholesteryl esters, is required to support prostate cancer cell growth. This provides new insights into the relationship between extracellular cholesterol, intracellular cholesterol metabolism, and prostate cancer cell growth and the potential mechanisms linking hypercholesterolemia and more aggressive prostate cancer.
Collapse
Affiliation(s)
- Nikki L Raftopulos
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Tinashe C Washaya
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Andreas Niederprüm
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine, Ruprecht Karl University of Heidelberg, Baden-Wuerttemberg, Heidelberg, Germany
| | - Antonia Egert
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Mariam F Hakeem-Sanni
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Bianca Varney
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Atqiya Aishah
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Mariya L Georgieva
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Ellinor Olsson
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Diandra Z Dos Santos
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Biotechnology Program/RENORBIO, Health Sciences Center, Federal University of Espirito Santo, Vitoria, ES, Brazil
| | - Zeyad D Nassar
- Adelaide Medical School and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, South Australia, Australia.,South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Blake J Cochran
- School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Shilpa R Nagarajan
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Meghna S Kakani
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Jordan F Hastings
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - David R Croucher
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.,St Vincent's Hospital Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Kerry-Anne Rye
- School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
| | - Lisa M Butler
- Adelaide Medical School and Freemasons Centre for Male Health and Wellbeing, University of Adelaide, Adelaide, South Australia, Australia.,South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Thomas Grewal
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
| | - Andrew J Hoy
- School of Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
| |
Collapse
|
3
|
Meneses-Salas E, García-Melero A, Kanerva K, Blanco-Muñoz P, Morales-Paytuvi F, Bonjoch J, Casas J, Egert A, Beevi SS, Jose J, Llorente-Cortés V, Rye KA, Heeren J, Lu A, Pol A, Tebar F, Ikonen E, Grewal T, Enrich C, Rentero C. Annexin A6 modulates TBC1D15/Rab7/StARD3 axis to control endosomal cholesterol export in NPC1 cells. Cell Mol Life Sci 2019; 77:2839-2857. [PMID: 31664461 PMCID: PMC7326902 DOI: 10.1007/s00018-019-03330-y] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Revised: 09/30/2019] [Accepted: 10/01/2019] [Indexed: 01/23/2023]
Abstract
Cholesterol accumulation in late endosomes is a prevailing phenotype of Niemann-Pick type C1 (NPC1) mutant cells. Likewise, annexin A6 (AnxA6) overexpression induces a phenotype reminiscent of NPC1 mutant cells. Here, we demonstrate that this cellular cholesterol imbalance is due to AnxA6 promoting Rab7 inactivation via TBC1D15, a Rab7-GAP. In NPC1 mutant cells, AnxA6 depletion and eventual Rab7 activation was associated with peripheral distribution and increased mobility of late endosomes. This was accompanied by an enhanced lipid accumulation in lipid droplets in an acyl-CoA:cholesterol acyltransferase (ACAT)-dependent manner. Moreover, in AnxA6-deficient NPC1 mutant cells, Rab7-mediated rescue of late endosome-cholesterol export required the StAR-related lipid transfer domain-3 (StARD3) protein. Electron microscopy revealed a significant increase of membrane contact sites (MCS) between late endosomes and ER in NPC1 mutant cells lacking AnxA6, suggesting late endosome-cholesterol transfer to the ER via Rab7 and StARD3-dependent MCS formation. This study identifies AnxA6 as a novel gatekeeper that controls cellular distribution of late endosome-cholesterol via regulation of a Rab7-GAP and MCS formation.
Collapse
Affiliation(s)
- Elsa Meneses-Salas
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
| | - Ana García-Melero
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain
| | - Kristiina Kanerva
- Faculty of Medicine, Anatomy, University of Helsinki, 00014, Helsinki, Finland.,Minerva Foundation Institute for Medical Research, 00290, Helsinki, Finland
| | - Patricia Blanco-Muñoz
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
| | - Frederic Morales-Paytuvi
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
| | - Júlia Bonjoch
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
| | - Josefina Casas
- Research Unit on BioActive Molecules (RUBAM), Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain
| | - Antonia Egert
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia
| | - Syed S Beevi
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia
| | - Jaimy Jose
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia
| | - Vicenta Llorente-Cortés
- Lipids and Cardiovascular Pathology Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.,CIBERCV, Institute of Health Carlos III, Madrid, Spain.,Biomedical Research Institute of Barcelona-CSIC, Barcelona, Spain
| | - Kerry-Anne Rye
- School of Medical Sciences, University of New South Wales, Sydney, NSW, 2052, Australia
| | - Joerg Heeren
- Department of Biochemistry and Molecular Biology II: Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Albert Lu
- Department of Biochemistry, Stanford University School of Medicine, Stanford, USA
| | - Albert Pol
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avaçats (ICREA), 08010, Barcelona, Spain
| | - Francesc Tebar
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain.,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain
| | - Elina Ikonen
- Faculty of Medicine, Anatomy, University of Helsinki, 00014, Helsinki, Finland.,Minerva Foundation Institute for Medical Research, 00290, Helsinki, Finland
| | - Thomas Grewal
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia.
| | - Carlos Enrich
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain. .,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
| | - Carles Rentero
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, 08036, Barcelona, Spain. .,Centre de Recerca Biomèdica CELLEX, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
| |
Collapse
|
4
|
Cairns R, Fischer AW, Blanco-Munoz P, Alvarez-Guaita A, Meneses-Salas E, Egert A, Buechler C, Hoy AJ, Heeren J, Enrich C, Rentero C, Grewal T. Altered hepatic glucose homeostasis in AnxA6-KO mice fed a high-fat diet. PLoS One 2018; 13:e0201310. [PMID: 30110341 PMCID: PMC6093612 DOI: 10.1371/journal.pone.0201310] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 07/12/2018] [Indexed: 12/12/2022] Open
Abstract
Annexin A6 (AnxA6) controls cholesterol and membrane transport in endo- and exocytosis, and modulates triglyceride accumulation and storage. In addition, AnxA6 acts as a scaffolding protein for negative regulators of growth factor receptors and their effector pathways in many different cell types. Here we investigated the role of AnxA6 in the regulation of whole body lipid metabolism and insulin-regulated glucose homeostasis. Therefore, wildtype (WT) and AnxA6-knockout (KO) mice were fed a high-fat diet (HFD) for 17 weeks. During the course of HFD feeding, AnxA6-KO mice gained less weight compared to controls, which correlated with reduced adiposity. Systemic triglyceride and cholesterol levels of HFD-fed control and AnxA6-KO mice were comparable, with slightly elevated high density lipoprotein (HDL) and reduced triglyceride-rich lipoprotein (TRL) levels in AnxA6-KO mice. AnxA6-KO mice displayed a trend towards improved insulin sensitivity in oral glucose and insulin tolerance tests (OGTT, ITT), which correlated with increased insulin-inducible phosphorylation of protein kinase B (Akt) and ribosomal protein S6 kinase (S6) in liver extracts. However, HFD-fed AnxA6-KO mice failed to downregulate hepatic gluconeogenesis, despite similar insulin levels and insulin signaling activity, as well as expression profiles of insulin-sensitive transcription factors to controls. In addition, increased glycogen storage in livers of HFD- and chow-fed AnxA6-KO animals was observed. Together with an inability to reduce glucose production upon insulin exposure in AnxA6-depleted HuH7 hepatocytes, this implicates AnxA6 contributing to the fine-tuning of hepatic glucose metabolism with potential consequences for the systemic control of glucose in health and disease.
Collapse
Affiliation(s)
- Rose Cairns
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Alexander W. Fischer
- Department of Biochemistry and Molecular Biology II: Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Patricia Blanco-Munoz
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Centre de Recerca Biomèdica CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
| | - Anna Alvarez-Guaita
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Centre de Recerca Biomèdica CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
| | - Elsa Meneses-Salas
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Centre de Recerca Biomèdica CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
| | - Antonia Egert
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Christa Buechler
- Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany
| | - Andrew J. Hoy
- Discipline of Physiology, School of Medical Science, Sydney Medical School, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia
| | - Joerg Heeren
- Department of Biochemistry and Molecular Biology II: Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Carlos Enrich
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Centre de Recerca Biomèdica CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
| | - Carles Rentero
- Departament de Biomedicina, Unitat de Biologia Cel·lular, Centre de Recerca Biomèdica CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
- * E-mail: (TG); (CR)
| | - Thomas Grewal
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- * E-mail: (TG); (CR)
| |
Collapse
|
5
|
Kanta Goswami S, Banerjee S, Saha P, Chakraborty P, Kabir SN, Karimzadeh MA, Mohammadian F, Mashayekhy M, Saldeen P, Kallen K, Karlstrom PO, Rodrigues-Wallberg KA, Salerno A, Nazzaro A, Di Iorio L, Marino S, Granato C, Landino G, Pastore E, Ghoshdastidar B, Chakraborty C, Ghoshdastidar BN, Ghoshdastidar S, Partsinevelos GA, Papamentzelopoulou M, Mavrogianni D, Marinopoulos S, Dinopoulou V, Theofanakis C, Anagnostou E, Loutradis D, Franz C, Nieuwland R, Montag M, Boing A, Rosner S, Germeyer A, Strowitzki T, Toth B, Mohamed M, Vlismas A, Sabatini L, Caragia A, Collins B, Leach A, Zosmer A, Al-Shawaf T, Beyhan Z, Fisch JD, Danner C, Keskintepe L, Aydin Y, Ayca P, Oge T, Hassa H, Papanikolaou E, Pados G, Grimbizis G, Bili H, Karastefanou K, Fatemi H, Kyrou D, Humaidan P, Tarlatzis B, Gungor F, Karamustafaoglu B, Iyibozkurt AC, Ozsurmeli M, Bastu E, Buyru F, Di Emidio G, Vitti M, Mancini A, Baldassarra T, D'Alessandro AM, Polsinelli F, Tatone C, Leperlier F, Lammers J, Dessolle L, Lattes S, Barriere P, Freour T, Elodie P, Assou S, Van den Abbeel E, Arce JC, Hamamah S, Assou S, Dechaud H, Haouzi D, Van den Abbeel E, Arce JC, Hamamah S, Tiplady S, Johnson S, Jones G, Ledger W, Eizadyar N, Ahmad Nia S, Seyed Mirzaie M, Azin SA, Yazdani Safa M, Onaran Y, Iltemir Duvan C, Keskin E, Ayrim A, Kafali H, Kadioglu N, Guler B, Var T, Cicek MN, Batioglu AS, Lichtblau I, Olivennes F, de Mouzon J, Dumont M, Junca AM, Cohen-Bacrie M, Hazout A, Belloc S, Cohen-Bacrie P, Allegra A, Marino A, Sammartano F, Coffaro F, Scaglione P, Gullo S, Volpes A, Cohen-Bacrie P, Cohen-Bacrie M, Hazout A, Lichtblau I, Dumont M, Junca AM, Belloc S, Prisant N, de Mouzon J, Saare M, Vaidla K, Salumets A, Peters M, Jindal UN, Thakur M, Shvell V, Diamond MP, Awonuga AO, Veljkovic M, Macanovic B, Milacic I, Borogovac D, Arsic B, Pavlovic D, Lekic D, Bojovic Jovic D, Garalejic E, Jayaprakasan K, Eljabu H, Hopkisson J, Campbell B, Raine-Fenning N, Kop P, van Wely M, Mol BW, Melker AA, Janssens PMW, Nap A, Arends B, Roovers JPWR, Ruis H, Repping S, van der Veen F, Mochtar MH, Sargin A, Yilmaz N, Gulerman C, Guven A, Polat B, Ozel M, Bardakci Y, Vidal C, Giles J, Remohi J, Pellicer A, Garrido N, Javdani M, Fallahzadeh H, Davar R, Sheibani H, Leary C, Killick S, Sturmey RG, Kim SG, Lee KH, Park IH, Sun HG, Lee JH, Kim YY, Choi EM, Van Loendersloot LL, Van Wely M, Repping S, Bossuyt PMM, Van Der Veen F, Roychoudhury Sarkar M, Roy D, Sahu R, Bhattacharya J, Eguiluz Gutierrez- Barquin I, Sanchez Sanchez V, Torres Afonso A, Alvarez Sanchez M, De Leon Socorro S, Molina Cabrillana J, Seara Fernandez S, Garcia Hernandez JA, Ozkan ZS, Simsek M, Kumbak B, Atilgan R, Sapmaz E, Agirregoikoa JA, DePablo JL, Abanto E, Gonzalez M, Anarte C, Barrenetxea G, Aleyasin A, Mahdavi A, Agha Hosseini M, Safdarian L, Fallahi P, Bahmaee F, Guler B, Kadioglu N, Sarikaya E, Cicek MN, Batioglu AS, Segawa T, Teramoto S, Tsuchiyama S, Miyauchi O, Watanabe Y, Ohkubo T, Shozu M, Ishikawa H, Yelian F, Papaioannou S, Knowles T, Aslam M, Milnes R, Takashima A, Takeshita N, Kinoshita T, Chapman MG, Kilani S, Ledger W, Dadras N, Parsanezhad ME, Zolghadri J, Younesi M, Floehr J, Dietzel E, Wessling J, Neulen J, Rosing B, Tan S, Jahnen-Dechent W, Lee KS, Joo JK, Son JB, Joo BS, Risquez F, Confino E, Llavaneras F, Marval I, D'Ommar G, Gil M, Risquez M, Lozano L, Paublini A, Piras M, Risquez A, Prochazka R, Blaha M, Nemcova L, Weghofer A, Kim A, Barad DH, Gleicher N, Kilic Y, Bastu E, Ergun B, Howard B, Weiss H, Doody K, Dietzel E, Wessling J, Floehr J, Schafer C, Ensslen S, Denecke B, Neulen J, Veitinger T, Spehr M, Tropartz T, Tolba R, Egert A, Schorle H, Jahnen-Dechent W, Bastu E, Alanya S, Yumru H, Ergun B. FEMALE (IN)FERTILITY. Hum Reprod 2012. [DOI: 10.1093/humrep/27.s2.80] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|